BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 15, 2022 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company…

Generated by Feedzy